Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Altimmune (ALT – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The company’s shares ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT stock is a Buy.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two ...

NASDAQ:ALT opened at $6.65 on Friday. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.05. The business’s 50-day moving average price is $6.85 and its two-hundred day moving average ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...

Altimmune, Inc. (NASDAQ:ALT – Free Report) – Stock analysts at B. Riley increased their FY2025 earnings estimates for Altimmune in a research note issued on Friday, February 28th. B.

Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...